A 38-year-old woman from Bangalore with a 3-year history of seropositive rheumatoid arthritis (RF+, anti-CCP+) on methotrexate monotherapy presents with acute onset of severe pain, erythema, and swelling of the right knee. Synovial fluid analysis shows: WBC 45,000/μL (85% neutrophils), negative bacterial culture, negative crystal analysis. Imaging shows no acute fracture. She denies recent trauma or fever. What is the most likely explanation for this acute flare despite ongoing DMARD therapy?

Explanation

## Acute Flare of RA: Pathological Basis ### Clinical Context This patient has: - **Established seropositive RA** (RF+, anti-CCP+) with 3-year duration - **Negative bacterial culture** → rules out septic arthritis - **Negative crystal analysis** → rules out crystal arthropathy - **No trauma or fever** → reduces likelihood of mechanical injury or infection - **On methotrexate monotherapy** → suggests suboptimal control (MTX alone achieves remission in ~30% of RA patients) ### Pathological Mechanism of RA Flare **Key Point:** Acute RA flares represent exacerbation of the underlying Type IV hypersensitivity response with surge in pro-inflammatory cytokine production. ### Neutrophil Recruitment in Acute Flares 1. **TNF-α and IL-6 surge** from activated macrophages and T cells in the synovium 2. **IL-8 (CXCL8) production** by synovial fibroblasts and endothelial cells 3. **Complement activation** (both classical and alternative pathways) via immune complexes and direct cell activation 4. **C5a generation** → potent neutrophil chemoattractant 5. **Neutrophil infiltration** → synovial fluid WBC rises to 10,000–50,000/μL (predominantly neutrophils) **High-Yield:** The synovial fluid profile (WBC 45,000/μL with 85% neutrophils) is **pathognomonic for acute inflammatory arthritis**, not sepsis. In septic arthritis, WBC typically exceeds 50,000/μL and cultures are positive. ### Why Methotrexate Monotherapy May Be Insufficient | Aspect | Methotrexate Alone | MTX + TNF Inhibitor | |--------|-------------------|---------------------| | **Remission rate** | ~30% | ~50–60% | | **TNF-α suppression** | Modest | Profound | | **IL-6 suppression** | Partial | Partial | | **Osteoclast inhibition** | Moderate | Excellent | | **Flare risk** | Higher | Lower | **Clinical Pearl:** The presence of anti-CCP antibodies predicts aggressive disease and erosive progression. This patient likely requires escalation to combination therapy (MTX + biologic) or switch to a TNF inhibitor. ### Histopathology of Acute Flare Synovial biopsy during flare shows: - **Massive neutrophil infiltration** in synovial fluid and sublining - **Activated macrophages** and T cells in synovial lining - **Increased vascularity** and endothelial activation - **Elevated cytokine production** (TNF-α, IL-6, IL-8, IL-17) - **Complement deposition** (C3, C4) on synovial endothelium ### Why Complement Activation Occurs 1. **Immune complex formation**: RF + IgG immune complexes activate classical pathway 2. **Alternative pathway**: Direct activation by synovial cells and neutrophil debris 3. **C3a and C5a generation** → further neutrophil recruitment and mast cell degranulation **Mnemonic: FLARE = Fibroblast activation → Lymphocyte recruitment → Amplification via cytokines → Recruitment of neutrophils → Exudation** ### Management Implications - **Do NOT treat empirically for sepsis** (negative culture, no fever) - **Do NOT assume crystal disease** (negative analysis, typical RA presentation) - **Escalate DMARD therapy**: Add TNF inhibitor or switch to biologic - **Consider intra-articular corticosteroid** for symptomatic relief while awaiting biologic effect [cite:Robbins 10e Ch 6; Harrison 21e Ch 335]